Can bone scans guide therapy with radium-223 dichloride for prostate cancer bone metastases?

References

• FlorimonteLDellavedovaLMaffioliLSRadium-223 dichloride in clinical practice: a reviewEur J Nucl Med Mol Imaging201643101896190927121689
   PubMed Web of Science ®Google Scholar
• WilsonJMParkerCThe safety and efficacy of radium-223 dichloride for the treatment of advanced prostate cancerExpert Rev Anticancer Ther201616991191827501059
   PubMed Web of Science ®Google Scholar
• The American Cancer Society [webpage on the Internet]The American Cancer Society: Key Statistics for Prostate Cancer Facts [Updated January 5, 2017] Available from: https://www.cancer.org/cancer/prostate-cancer/about/key-statistics.htmlAccessed August 18, 2017
   Google Scholar
• El-AmmJAragon-ChingJBRadium-223 for the treatment of castration-resistant prostate cancerOnco Targets Ther20151811031109
   Google Scholar
• HarrisWPMostaghelEANelsonPSMontgomeryBAndrogen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletionNat Clin Pract Urol200962768519198621
   PubMedGoogle Scholar
• TilkiDSchaefferEMEvansCPUnderstanding mechanisms of resistance in metastatic castration-resistant prostate cancer: the role of the androgen receptorEur Urol Focus20162549950528723515
   PubMedGoogle Scholar
• CostaLBadiaXChowELiptonAWardleyAImpact of skeletal complications on patients’ quality of life, mobility, and functional independenceSupport Care Cancer200816887988918392862
   PubMed Web of Science ®Google Scholar
• MottetNBellmuntJBollaMEAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancerActas Urol Esp20113556557921757258
   PubMed Web of Science ®Google Scholar
• ParkerCNilssonSHeinrichDALSYMPCA InvestigatorsAlpha emitter radium-223 and survival in metastatic prostate cancerN Engl J Med20133501616551664
   Google Scholar
• SaadFCharlesJGillessenSRadium-223 and concomitant therapies in patients with metastatic castration-resistant prostate cancer: an international, early access, open-label, single-arm phase 3b trialLancet Oncol20161791306131627473888
   PubMed Web of Science ®Google Scholar
• Anido HerranzUFernández CalvoOAfonso AfonsoFJRadium-223 dichloride: a new paradigm in the treatment of prostate cancerExpert Rev Anticancer Ther20151533934825555355
   PubMed Web of Science ®Google Scholar
• MulfordDScheinbergDJurcicJThe promise of targeted alpha-particle therapyJ Nucl Med200546suppl 1199S204S15653670
   PubMedGoogle Scholar
• NilssonSFranzenLParkerCTwo-year survival follow-up of the randomized double-blind, placebo-controlled phase II study of radium-223 chloride in patients with castration-resistant prostate cancer and bone metastasesClin Genitourin Cancer2013111202623021204
   PubMed Web of Science ®Google Scholar
• SarotorOColemanRNilssonSEffect of radium 223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomized trialLancet Oncol201415773874624836273
   PubMed Web of Science ®Google Scholar
• EtchebehereECAraujoJCFoxPSSwanstonNMMacapinlacHARohrenEMPrognostic factors in patients treated with 223 Ra: the role of skeletal tumor burden on baseline 18F-fluoride PET/CT in predicting overall survivalJ Nucl Med20155681177118426069307
   PubMed Web of Science ®Google Scholar
• BräuerARahbarKKonnertJBögemannMSteggerLDiagnostic value of additional 68Ga-PSMA-PET before 223 Ra-dichloride therapy in patients with metastatic prostate carcinomaNuklearmedizin2017561142228074210
   PubMedGoogle Scholar
• AhmadzadehfarHAzgomiKHauserSGa-PSMA-11 PET as a gatekeeper for the treatment of metastatic prostate cancer with 223Ra: proof of conceptJ Nucl Med201758343844427660148
   PubMed Web of Science ®Google Scholar
• SartorOColemanRNillsonSAn exploratory analysis of alkaline phosphatase, lactate dehydrogenase, and prostate-specific antigen dynamics in the phase 3 ALSYMPCA trial with radium-223Ann Oncol20172851090109728453701
   PubMed Web of Science ®Google Scholar
• SweeneyCJChenYHCarducciMChemohormonal therapy in metastatic hormone-sensitive prostate cancerN Engl J Med2015373873774626244877
   PubMed Web of Science ®Google Scholar
• RathkopfDESmithMRde BonoJSUpdated interim efficacy analysis and long-term safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients without prior chemotherapy (COU-AA-302)Eur Urol201466581582524647231
   PubMed Web of Science ®Google Scholar
• CrawfordEDHiganoCSShoreNDHussainMPetrylakDPTreating patients with metastatic castration resistant prostate cancer: a comprehensive review of available therapiesJ Urol201519461537154726196735
   PubMed Web of Science ®Google Scholar
• LiepeKShintoAFrom palliative therapy to prolongation of survival: (223) RaCl2 in the treatment of bone metastasesTher Adv Med Oncol20168429430427482288
   PubMed Web of Science ®Google Scholar
• JamesNDBloomfieldDLuscombeCThe changing pattern of management for hormone-refractory, metastatic prostate cancerProstate Cancer Prostatic Dis20069322122916801939
   PubMed Web of Science ®Google Scholar
• PiffanelliADafermouAGigantiMItalian Association of Nuclear Medicine (AINM)Radionuclide therapy for painful bone metastases. An Italian multicentre observational study. Writing Committee of an Ad Hoc Study GroupQ J Nucl Med200145110010711456368
   PubMedGoogle Scholar
• SartorOIsotope therapy for castrate-resistant prostate cancer: unique sequencing and combinationsCancer J201622534234627749328
   PubMed Web of Science ®Google Scholar
• SongYPEllisTWalshawRComparing clinical outcomes for radium-223: do older patients do worse?Int J Radiat Oncol Biol Phys201798495595728365163
   PubMed Web of Science ®Google Scholar
• DuYDe VincentisGFantiSPractical recommendations for radium-223 treatment of metastatic castration-resistant prostate cancerEur J Nucl Med Mol Imaging201744101671167828631036
   PubMed Web of Science ®Google Scholar